Drug Trial Radar · NCT00209417
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
Last checked: Nov 19, 2026Latest source record: Oct 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
656
Actual
Start
Jun 2005
Primary completion
May 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- ABX CRO; Examination Management Services Inc.; Covance; Quintiles, Inc.; Averion International Corporation
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
Conditions
- Renal Insufficiency
- Diabetes Mellitus
Interventions
Iodixanol 320-Arm 1Drug
Iopamidol 300-Arm 2Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.Time frame: From baseline up to 3 days post contrast administration.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
GE Healthcare
Amersham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.